Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
- Trade
- Markets
- Copy
- Contests
- News
- 24/7
- Calendar
- Q&A
- Chats
SYMBOL
LAST
ASK
BID
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6798.39
6798.39
6798.39
6857.86
6780.45
-84.33
-1.23%
--
DJI
Dow Jones Industrial Average
48908.71
48908.71
48908.71
49340.90
48829.10
-592.58
-1.20%
--
IXIC
NASDAQ Composite Index
22540.58
22540.58
22540.58
22841.28
22461.14
-363.99
-1.59%
--
USDX
US Dollar Index
97.700
97.780
97.700
97.790
97.600
-0.120
-0.12%
--
EURUSD
Euro / US Dollar
1.17896
1.17903
1.17896
1.18014
1.17655
+0.00108
+ 0.09%
--
GBPUSD
Pound Sterling / US Dollar
1.35635
1.35647
1.35635
1.35782
1.35081
+0.00331
+ 0.24%
--
XAUUSD
Gold / US Dollar
4858.29
4858.63
4858.29
4903.14
4655.10
+80.40
+ 1.68%
--
WTI
Light Sweet Crude Oil
63.776
63.806
63.776
64.128
62.146
+0.842
+ 1.34%
--
- All
- Chatrooms
- Groups
- Friends
am Swing trader 
Matthew 
Visxa Benfica 
@Sarkar 
Visxa Benfica
Visxa Benfica
Because it has rejected the old low and is retesting the supply zone around 65-66k
EuroTrader 
SlowBear ⛅ 
@Sarkar
Visxa Benfica
@Sarkar
Visxa Benfica
Setting a tight stop loss is an effective way to protect your account buddy
LOMERI 
Visxa Benfica
@LOMERIBut I don't quite agree with the idea that this is a major reversal right away
EuroTrader
Visxa Benfica
If it stays above 64k and closes strongly green on the 1H chart, we can push it up to 67-68k to retest resistance
Matthew
Visxa Benfica
Matthew
@Sarkar
- All
- Russia-Ukraine Conflict
- Middle East Flashpoint
Why Repligen (RGEN) Shares Are Sliding Today
Stock Story
What Happened?
Shares of biopharma manufacturing company Repligen Corporation fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales guidance for 2025.
During the event, President and CEO Olivier Loeillot stated that at the midpoint of the company's guidance, 2025 sales were $733 million. Repligen, which described itself as a 'pure bioprocessing play,' focuses on creating materials used in the manufacturing of biologic drugs. The negative stock reaction suggested investors may have been underwhelmed by the sales forecast, potentially expecting a more robust outlook for the year ahead.
What Is The Market Telling Us
Repligen’s shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 7.8% on the news that the company reported strong second-quarter 2025 financial results and raised its full-year guidance.
The life sciences company announced that its revenue climbed 15% year-over-year to $182 million, driven by growth across all its franchises and geographies. Profitability also saw a substantial increase, with net income rising to $14.87 million from $5.71 million in the same quarter last year. A key indicator of future performance, company orders, grew by over 20%. Buoyed by these strong results, Repligen lifted its full-year 2025 revenue forecast to a range of $715 million to $735 million.
Repligen is flat since the beginning of the year, and at $162.71 per share, it is trading close to its 52-week high of $174.24 from January 2025. Investors who bought $1,000 worth of Repligen’s shares 5 years ago would now be looking at an investment worth $766.60.
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2026 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
Become a signal provider
Help Center
Dark Mode
Price Up/Down Colors
Log In
Sign Up